Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorShandong Boan Biotechnology Co., Ltd
About this trial
This is a first-in-human (FIH), multicenter, open-label Phase I study to evaluate the safety, tolerability, PK profile, immunogenicity, and preliminary efficacy of BA1302 in patients with advanced solid malignancies. The study includes a dose-escalation phase (Part A) and a dose-expansion phase (Part B).
Eligibility criteria
Qualifiers
1. Metastatic or unresectable solid malignancy that is histologically or cytologically confirmed. Patients who have progressed on or after standard therapy, or are intolerant of standard therapy, or have no appropriate standard therapy available.
Part A: Advanced malignant solid tumors;
Part B: Metastatic melanoma, Advanced breast cancer, Advanced Non-small cell lung cancer (NSCLC), Advanced pancreatic adenocarcinoma.
2.Participants should be able to provide adequate tumor tissue for biomarker analysis
Disqualifiers
1. Malignant disease within 5 years prior to the first dose of investigational drug other than that being treated in this study. Except completely resected basal cell carcinoma, cutaneous squamous cell skin carcinoma and papillary thyroid carcinoma and completely resected carcinoma in situ of any type.
2. Received any chemotherapy, radiotherapy, targeted therapy, cell therapy, immunotherapy, ADC medication or other anti-cancer treatment within 28 days prior to the first dose.
3.History of severe hypersensitivity reactions to any ingredient of study drugs.
4.Pregnant or lactating women.
Trial design
Treatments tested in this trial
- BA1302
Treatment groups
167 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov